These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 17066144)

  • 1. Links between Alzheimer's disease and diabetes.
    Sun MK; Alkon DL
    Timely Top Med Cardiovasc Dis; 2006 Oct; 10():E24. PubMed ID: 17066144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Links between Alzheimer's disease and diabetes.
    Sun MK; Alkon DL
    Drugs Today (Barc); 2006 Jul; 42(7):481-9. PubMed ID: 16894402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin resistance, inflammation, and cognition in Alzheimer's Disease: lessons for multiple sclerosis.
    Watson GS; Craft S
    J Neurol Sci; 2006 Jun; 245(1-2):21-33. PubMed ID: 16631207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of memory by insulin and glucose: neuropsychological observations in Alzheimer's disease.
    Watson GS; Craft S
    Eur J Pharmacol; 2004 Apr; 490(1-3):97-113. PubMed ID: 15094077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. O-GlcNAc modification in diabetes and Alzheimer's disease.
    Dias WB; Hart GW
    Mol Biosyst; 2007 Nov; 3(11):766-72. PubMed ID: 17940659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study.
    Hampel H; Ewers M; Bürger K; Annas P; Mörtberg A; Bogstedt A; Frölich L; Schröder J; Schönknecht P; Riepe MW; Kraft I; Gasser T; Leyhe T; Möller HJ; Kurz A; Basun H
    J Clin Psychiatry; 2009 Jun; 70(6):922-31. PubMed ID: 19573486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nitric oxide inhibits insulin-degrading enzyme activity and function through S-nitrosylation.
    Cordes CM; Bennett RG; Siford GL; Hamel FG
    Biochem Pharmacol; 2009 Mar; 77(6):1064-73. PubMed ID: 19154729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alzheimer's disease: from pathology to therapeutic approaches.
    Jakob-Roetne R; Jacobsen H
    Angew Chem Int Ed Engl; 2009; 48(17):3030-59. PubMed ID: 19330877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic links between diabetes and Alzheimer's disease.
    Maher PA; Schubert DR
    Expert Rev Neurother; 2009 May; 9(5):617-30. PubMed ID: 19402773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Common pathological processes and transcriptional pathways in Alzheimer's disease and type 2 diabetes.
    Jones A; Kulozik P; Ostertag A; Herzig S
    J Alzheimers Dis; 2009; 16(4):787-808. PubMed ID: 19387113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Restored degradation of the Alzheimer's amyloid-beta peptide by targeting amyloid formation.
    Crouch PJ; Tew DJ; Du T; Nguyen DN; Caragounis A; Filiz G; Blake RE; Trounce IA; Soon CP; Laughton K; Perez KA; Li QX; Cherny RA; Masters CL; Barnham KJ; White AR
    J Neurochem; 2009 Mar; 108(5):1198-207. PubMed ID: 19141082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amyloid-dependent triosephosphate isomerase nitrotyrosination induces glycation and tau fibrillation.
    Guix FX; Ill-Raga G; Bravo R; Nakaya T; de Fabritiis G; Coma M; Miscione GP; Villà-Freixa J; Suzuki T; Fernàndez-Busquets X; Valverde MA; de Strooper B; Muñoz FJ
    Brain; 2009 May; 132(Pt 5):1335-45. PubMed ID: 19251756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Down-regulation of insulin-degrading enzyme by presenilin 1 V97L mutant potentially underlies increased levels of amyloid beta 42.
    Qin W; Jia J
    Eur J Neurosci; 2008 May; 27(9):2425-32. PubMed ID: 18445230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of gamma-secretase activity in Alzheimer's disease.
    Zhou S; Zhou H; Walian PJ; Jap BK
    Biochemistry; 2007 Mar; 46(10):2553-63. PubMed ID: 17298085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promoter polymorphisms which modulate insulin degrading enzyme expression may increase susceptibility to Alzheimer's disease.
    Zuo X; Jia J
    Brain Res; 2009 Jan; 1249():1-8. PubMed ID: 18996360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins.
    Ray S; Britschgi M; Herbert C; Takeda-Uchimura Y; Boxer A; Blennow K; Friedman LF; Galasko DR; Jutel M; Karydas A; Kaye JA; Leszek J; Miller BL; Minthon L; Quinn JF; Rabinovici GD; Robinson WH; Sabbagh MN; So YT; Sparks DL; Tabaton M; Tinklenberg J; Yesavage JA; Tibshirani R; Wyss-Coray T
    Nat Med; 2007 Nov; 13(11):1359-62. PubMed ID: 17934472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What is 'early onset dementia'?
    Miyoshi K
    Psychogeriatrics; 2009 Jun; 9(2):67-72. PubMed ID: 19604328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of borderline diabetes on the risk of dementia and Alzheimer's disease.
    Xu W; Qiu C; Winblad B; Fratiglioni L
    Diabetes; 2007 Jan; 56(1):211-6. PubMed ID: 17192484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor necrosis factor-induced cerebral insulin resistance in Alzheimer's disease links numerous treatment rationales.
    Clark I; Atwood C; Bowen R; Paz-Filho G; Vissel B
    Pharmacol Rev; 2012 Oct; 64(4):1004-26. PubMed ID: 22966039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The coming problem of HIV-associated Alzheimer's disease.
    Alisky JM
    Med Hypotheses; 2007; 69(5):1140-3. PubMed ID: 17433562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.